| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1988.6.8.1321 |
| P953 | full work available at URL | http://intl.jco.org/cgi/content/abstract/6/8/1321 |
| https://ascopubs.org/doi/pdfdirect/10.1200/JCO.1988.6.8.1321 | ||
| P698 | PubMed publication ID | 3411343 |
| P2093 | author name string | K. A. Rodvold | |
| D. A. Tewksbury | |||
| D. A. Rushing | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| oncology | Q162555 | ||
| P304 | page(s) | 1321-1327 | |
| P577 | publication date | 1988-08-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Doxorubicin clearance in the obese | |
| P478 | volume | 6 |
| Q36004460 | A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer |
| Q36468048 | A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients |
| Q41942293 | A mathematical model for thermosensitive liposomal delivery of Doxorubicin to solid tumour |
| Q30417300 | A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model |
| Q33358496 | Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability |
| Q46028247 | Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. |
| Q39012759 | Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. |
| Q35024342 | Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment |
| Q37348793 | Anthropomorphic measurements and event-free survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group |
| Q34428550 | Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia |
| Q43746121 | Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes |
| Q52465225 | Bayesian estimation of doxorubicin pharmacokinetic parameters |
| Q40369664 | Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. |
| Q35949084 | Cardiac toxicity of high-dose chemotherapy |
| Q24628695 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management |
| Q81527118 | Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger |
| Q38700644 | Clinical pharmacology of cancer chemotherapy in children. |
| Q59289581 | Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer |
| Q52888199 | Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women. |
| Q45122668 | Disposition of high-dose methotrexate in an obese cancer patient |
| Q68640932 | Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters |
| Q36210124 | Effect of body mass index on the outcome of children with acute myeloid leukemia. |
| Q34053786 | Effects of obesity on pharmacokinetics implications for drug therapy |
| Q67874965 | Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study |
| Q44357042 | Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme |
| Q34459665 | Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing |
| Q43567644 | Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. |
| Q71730035 | Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry |
| Q36216242 | Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia |
| Q35139846 | Impact of obesity in the setting of high-dose chemotherapy |
| Q34729831 | Important aspects of nutrition in children with cancer |
| Q37706167 | Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type |
| Q37400113 | Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review |
| Q40748711 | Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research |
| Q41340275 | Isolated liver perfusion for liver metastases: pharmacokinetic advantage? |
| Q37117167 | Late congestive heart failure after hematopoietic cell transplantation |
| Q92048382 | Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report |
| Q35826177 | Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling |
| Q90159835 | Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia |
| Q36085651 | Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. |
| Q26786829 | Obesity and cancer: mechanistic insights from transdisciplinary studies |
| Q26863606 | Obesity in cancer survival |
| Q41558088 | Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice |
| Q37695910 | Pharmacokinetics of doxorubicin in pregnant women |
| Q35579412 | Pharmacology of Anticancer Drugs in the Elderly Population |
| Q46770269 | Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors |
| Q77761715 | Practical treatment guide for dose individualisation in cancer chemotherapy |
| Q37034836 | Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer |
| Q69361463 | Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution |
| Q38838517 | Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity |
| Q64969762 | Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. |
| Q55406137 | Sex Differences in Cancer: Epidemiology, Genetics and Therapy. |
| Q36877575 | Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes. |
| Q21142666 | The average body surface area of adult cancer patients in the UK: a multicentre retrospective study |
| Q35611950 | The role of body mass index in survival outcome for lymphoma patients: US intergroup experience |
| Q37650674 | Towards a Model-Based Dose Recommendation for Doxorubicin in Children. |
| Q43524982 | Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women |
| Q38156036 | Treatment-related cardiotoxicity in survivors of childhood cancer |
| Q38056012 | Trimming the fat: obesity and hematopoietic cell transplantation |
| Q35826324 | What is the best size descriptor to use for pharmacokinetic studies in the obese? |
Search more.